Furthermore, treating AML cell lines with the PKC inhibitor, enzastaurin, blocks the phosphorylation of PKCα and its downstream target, ERK, and also prevents PKCα membrane recruitment10. This evidence concerns the gene PRRT2 and acute myeloid leukemia.